Prestige Consumer Healthcare Inc.
PBH$3.09B
Mid CapNASDAQBiotechnology🇺🇸North America600 employees
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
PBH News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
HD204
Lung Cancer
HD201
HER2 Positive Breast Cancer
PBP1510 (400mg/16mL)
Pancreatic Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HD204 | Phase 3 | Lung Cancer | - | - |
HD201 | Phase 3 | HER2 Positive Breast Cancer | - | - |
PBP1510 (400mg/16mL) | Phase 2 | Pancreatic Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply